This document serves as a formal Author Correction for the study titled "Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans," originally published in Cell Research in March 2024. While the core findings of the study remain unchanged, this correction provides essential technical clarifications to ensure the scientific record is accurate and reproducible.
Context and Significance
The original research investigated atherosclerosis—the chronic inflammatory buildup of plaque in arterial walls—and explored whether targeting pro-inflammatory T cells could offer a viable therapeutic strategy. Specifically, the authors focused on the PD-1/PD-L1 pathway. In high-stakes immunology, precise terminology and data labeling are paramount for understanding cell-to-cell interactions and cytokine signaling. This correction addresses several errata that appeared in the initial publication.
Technical and Methodological Clarifications
1. Micro-pipette Adhesion Assay
A key correction involves the description of the biophysical techniques used. The original text incorrectly referred to a "micro-peptide" assay. The authors have clarified that they utilized a micro-pipette adhesion assay. This sophisticated method is used to qualitatively and quantitatively determine the in-situ interaction between primary CD64+ cells and PD-1+ T cells. This assay was critical for evaluating how Nivolumab (an anti-PD-1 monoclonal antibody) modulates these interactions.
2. Immunological Nomenclature: FcγR-binding
The authors have updated the terminology from "Fc-binding" to "FcγR-binding" (and "non-FcγR-binding"). This distinction is vital for immunologists, as Fcγ receptors (FcγR) are the specific receptors for the Fc region of IgG antibodies. This clarification defines the exact mechanism by which therapeutic antibodies interact with immune cells in the context of atherosclerosis.
3. Cell Surface Marker Accuracy
In Figure 6a, a label was corrected from "CD45–" to "CD45+" for PD-L1 expressing cells. Since CD45 is a pan-leukocyte marker, this correction accurately identifies the cells as being of hematopoietic (immune) origin, which is central to the study's focus on immune-mediated inflammation.
Data Visualization and Reference Updates
The correction also addresses several visual and citation errors:
- Cytokine Concentrations: The Y-axis labels for IL-2 and IFN-γ in Figure 4g were corrected to accurately reflect concentrations in pg/mL. These pro-inflammatory cytokines are key indicators of T-cell activity.
- Heatmap Alignment: Cluster frequency annotations in Figure 3a were re-ordered to correctly match the corresponding data rows.
- Literature Integrity: Reference 53 was updated from a bioRxiv preprint to its final peer-reviewed version in PLoS ONE (2021), ensuring the foundational work on Rora expression in CD4+ T cells is properly cited.
Conclusion
The authors emphasize that these technical corrections do not alter the results or the final conclusions of the research. The primary discovery—that targeting specific pro-inflammatory T cells can potentially resolve atherosclerosis—remains robust and supported by the corrected data. These updates ensure that researchers building upon this work have the most accurate technical framework possible.
Summary updated